PPT-Patenting Biomarkers and Diagnostic Methods

Neil P Shull PhD JD Sterne Kessler Goldstein amp Fox PLLC FIRE Series LXIX March 8 2012 Overview of issues What can be patented Is it useful How much data is needed Potential prior art issues. Leslie M Shaw & John Q . Trojanowski. Magdalena Korecka. Michal Figurski. Teresa . Waligorska. Magdalena Brylska. Leona Fields. Nirali. Shah. Biomarker Core Aims for ADNI 3. Continue to collect, store, curate and track all . Prof Sigrid . Sterckx. , Ghent University. Dr. Julian Cockbain, European Patent Attorney, Gent and Oxford. Oxford, 24 June 2015. Translation. Patents can assist translation (getting science into practice) or it can hinder it.. Francesco Lissoni. 1,2. , Michele . Pezzoni. 2,3. , . Bianca . Potì. 4. , . Sandra . Romagnosi. 5. 1 . GREThA. – . Université. Bordeaux IV - France. 2 . CRIOS. . – Università "L. Bocconi", Milan - Italy. Raghu Kannan. “THE NEW . GOLD STANDARD. . IN . COMPANION . DIAGNOSTICS”. Introductory Slide. Current methods of detection. IHC: . Dako. –in accurate. PCR –amplifies . all . genes . FISH –works well; however, microscopic visualization of tumor regions is difficult. James L. Cook, DVM, . PhD. Director, Comparative Orthopaedic Lab & . Mizzou. . BioJoint. Center. cookjl@health.missouri.edu. Osteoarthritis (OA): . Everyone’s Problem. Markets. Canine. 78M companion dogs in US (2015 APPA Survey). Sid E. O’Bryant, Ph.D.. Sid.obryant@unthsc.edu. Blood Based Biomarkers PIA. Founding Goals of the PIA. Standardization & Best Practices for the field. Increasing access to data & virtual repository. Mike Chapman. University of Cambridge Department of Haematology. Novel agents have improved survival. What is a biomarker?. “A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”. 1996-2006. Francesco Lissoni. 1,2. , Michele Pezzoni. 2. , Bianca Potì. 3. , Sandra Romagnosi. 4. 1 . GREThA. . – . Université. Bordeaux IV - France. 2 . KITeS. . – Università "L. Bocconi", Milan - Italy. Paul Dagum, MD PhD. Mindstrong Health. National Alliance in Mental Health. Washington, CD. June 30, 2017 . CHALLENGES IN MENTAL HEALTH. LACK OF MEASUREMENT. Episodic, subjective measures in laboratory environments lack sensitivity — may fail to detect clinical change . Ruturaj R. Masvekar, PhD. Neuroimmunological Diseases Section (NDS). National Institute of Allergy and Infectious Diseases (NIAID). National Institutes of Health (NIH). 1. The efficacy of immunomodulatory treatments in MS decreases with age and disease evolution. Presented by: . Dr. Puneet Opal . Dr. Hayley McLoughlin. A Virtual Event. March 17-19, 2022. DISCLAIMER. 2022 AAC. A Virtual Event. March 17-19. PRESENTER DISCLOSURES. Dr. Puneet Opal (Northwestern University). May 2019. Available Diagnostic Technologies. 2. Disease Diagnostics. Page. Ancsin:. . 15-T-073. Companion Assays for the Diagnosis of Deficiencies in Triglyceride Clearance for the Treatment of Hypertriglyceridemia (HTG). Pragya Kumari. 1. , . Atanu. Bhattacharjee. 2. , Gajendra K. Vishwakarma. 1. 1. Indian Institute of Technology (ISM) Dhanbad, India, 826004. 2. Institute of . Acturial. . Sceience. and Data Analytics, UCSI University, Malaysia, 56000. Nfl. =neurofilament light; PDGFR. . =. platelet-derived growth factor receptor beta. ; . PET=positron emission tomography; p-tau=phosphorylated tau; RT-. QuIC. =real-time quaking-induced conversion; SNAP-25=.